VOL. I / NO. 07 / ABOUT
About Doctor TB-500
An independent editorial project and reading room for the TB-500 and Thymosin Beta-4 research literature.
What This Site Is
Doctor TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, Thymosin Beta-4. The research record on this compound spans wound healing, tendon and ligament repair, cardiac protection, hair follicle biology, traumatic brain injury, neurological axon regeneration, and two human Phase I pharmacokinetic trials — a genuinely heterogeneous literature that rewards a reading room.
We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The 'Doctor' in the name is editorial framing — a position this publication occupies relative to the research literature, as a careful reader, organizer, and summarizer of published findings. It is not a claim about clinical services, medical staff, or treatment capabilities. This site does not offer treatment, consultation, or prescription services of any kind.
Every quantitative claim on this site traces to a numbered citation in the references index. Findings are described at the dose, route, species, and outcome level documented in the source study. Where the evidence is limited, this site says so.
Regulatory Status of TB-500
TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length Thymosin Beta-4 has been investigated in Phase I human trials and in a Phase 2 ophthalmic trial; as of 2025, no FDA approval exists for systemic Tβ4 or for the TB-500 synthetic fragment in any indication.
TB-500 is listed on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is also captured by S0 (Non-Approved Substances). It is prohibited at all times — in-competition and out-of-competition — and classified as a non-Specified Substance carrying the maximum four-year sanction. At least one athlete has been sanctioned by the Canadian Centre for Ethics in Sport for TB-500 use.
TB-500 is not classified as a controlled substance under the US Controlled Substances Act.
This regulatory context is described accurately and without advocacy in either direction. It is part of the research record.
Editorial Standards
This site follows a strict citation policy: every quantitative claim maps to a specific numbered citation in the references list. Citations are drawn from PubMed-indexed journals, PubMed Central, ClinicalTrials.gov, and peer-reviewed reviews. Where a claim is derived from a review article rather than primary research, that is noted.
Where the evidence is from rodent models only, this site says 'in rodent models' rather than implying human generalizability. Where human data exists (the Tβ4 Phase I trials, the dry eye Phase 2), it is identified as human data and distinguished from the preclinical record. Where no peer-reviewed data exists — as in the TB-500 + BPC-157 combination — this site states that directly.
Content is not written by or reviewed by a physician. It is written by editors applying a defined citation protocol to publicly available published science. Questions about medical treatment should be directed to a licensed healthcare provider.
Contact: /contact.